Literature DB >> 22374738

Mediators of receptor tyrosine kinase activation in infantile fibrosarcoma: a Children's Oncology Group study.

Samantha Gadd1, Patricia Beezhold, Lawrence Jennings, David George, Katrin Leuer, Chiang-Ching Huang, Vicki Huff, Cristina Tognon, Poul H B Sorensen, Timothy Triche, Cheryl M Coffin, Elizabeth J Perlman.   

Abstract

Infantile fibrosarcoma (IFS; also known as cellular congenital mesoblastic nephroma, CMN, when in the kidney) is a rare, undifferentiated tumour often characterized by the ETV6-NTRK3 fusion transcript. Our goal was to identify downstream pathways, diagnostic markers and potential therapeutic targets for IFS/CMN. Global gene expression, reverse-phase protein array and ETV6-NTRK3 fusion analyses were performed on 14 IFS/CMN and compared with 41 other paediatric renal tumours. These analyses confirm significant receptor tyrosine kinase (RTK) activation, with evidence of PI3-Akt, MAPK and SRC activation. In particular, GAB2 docking protein, STAT5-pTyr-694, STAT3-pSer-729 and YAP-pSer-127 were elevated, and TAZ-pSer-89 was decreased. This provides mRNA and proteomic evidence that GAB2, STAT activation and phosphorylation of the Hippo pathway transcription co-activators YAP and TAZ contribute to the RTK signal transduction in IFS/CMN. All IFS/CMN tumours displayed a distinctive gene expression pattern that may be diagnostically useful. Unexpectedly, abundant ETV6-NTRK3 transcript copies were present in only 7/14 IFS, with very low copy number in 3/14. An additional 4/14 were negative by RT-PCR and absence of ETV6-NTRK3 was confirmed by FISH for both ETV6 and NTRK3. Therefore, molecular mechanisms other than ETV6-NTRK3 fusion are responsible for the development of some IFS/CMNs and the absence of ETV6-NTRK3 fusion products should not exclude IFS/CMN as a diagnosis.
Copyright © 2012 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22374738     DOI: 10.1002/path.4010

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  13 in total

1.  Spontaneous Regression in a Patient With Infantile Fibrosarcoma.

Authors:  Sameer Farouk Sait; Enrico Danzer; Daniel Ramirez; Michael P LaQuaglia; Meyers Paul
Journal:  J Pediatr Hematol Oncol       Date:  2018-05       Impact factor: 1.289

2.  Recurrent BRAF Gene Fusions in a Subset of Pediatric Spindle Cell Sarcomas: Expanding the Genetic Spectrum of Tumors With Overlapping Features With Infantile Fibrosarcoma.

Authors:  Yu-Chien Kao; Christopher D M Fletcher; Rita Alaggio; Leonard Wexler; Lei Zhang; Yun-Shao Sung; Dicle Orhan; Wei-Chin Chang; David Swanson; Brendan C Dickson; Cristina R Antonescu
Journal:  Am J Surg Pathol       Date:  2018-01       Impact factor: 6.394

3.  Expression of upstream and downstream targets of mTOR pathway in seven cases of secretory carcinoma of salivary gland origin.

Authors:  Marcos Custódio; Bruno Tavares Sedassari; Albina Altemani; Maria Fernanda Setúbal Destro Rodrigues; Fábio Daumas Nunes; Suzana Cantanhede Orsini Machado de Sousa
Journal:  Eur Arch Otorhinolaryngol       Date:  2020-06-23       Impact factor: 2.503

4.  Clear cell sarcoma of the kidney demonstrates an embryonic signature indicative of a primitive nephrogenic origin.

Authors:  Jenny Karlsson; Linda Holmquist Mengelbier; Cristina D Ciornei; Arlene Naranjo; Maureen J O'Sullivan; David Gisselsson
Journal:  Genes Chromosomes Cancer       Date:  2014-02-01       Impact factor: 5.006

5.  Intestinal congenital/infantile fibrosarcoma: a new clinico-pathological entity?

Authors:  Dominique Berrebi; Jean-Christophe Fournet; Françoise Boman; Monique Fabre; Pascale Philippe-Chomette; Sophie Branchereau; Paul Fréneaux; Dorothée Bouron-Dal Soglio; Jean Michon; Michel Peuchmaur
Journal:  Pediatr Surg Int       Date:  2015-02-05       Impact factor: 1.827

6.  Clinically relevant subsets identified by gene expression patterns support a revised ontogenic model of Wilms tumor: a Children's Oncology Group Study.

Authors:  Samantha Gadd; Vicki Huff; Chiang-Ching Huang; E Cristy Ruteshouser; Jeffrey S Dome; Paul E Grundy; Norman Breslow; Lawrence Jennings; Daniel M Green; J Bruce Beckwith; Elizabeth J Perlman
Journal:  Neoplasia       Date:  2012-08       Impact factor: 5.715

7.  Recurrent EML4-NTRK3 fusions in infantile fibrosarcoma and congenital mesoblastic nephroma suggest a revised testing strategy.

Authors:  Alanna J Church; Monica L Calicchio; Valentina Nardi; Alena Skalova; Andre Pinto; Deborah A Dillon; Carmen R Gomez-Fernandez; Namitha Manoj; Josh D Haimes; Joshua A Stahl; Filemon S Dela Cruz; Sarah Tannenbaum-Dvir; Julia L Glade-Bender; Andrew L Kung; Steven G DuBois; Harry P Kozakewich; Katherine A Janeway; Antonio R Perez-Atayde; Marian H Harris
Journal:  Mod Pathol       Date:  2017-11-03       Impact factor: 7.842

8.  Novel BRAF gene fusions and activating point mutations in spindle cell sarcomas with histologic overlap with infantile fibrosarcoma.

Authors:  Alyssa J Penning; Alyaa Al-Ibraheemi; Michael Michal; Brandon T Larsen; Soo-Jin Cho; Christina M Lockwood; Vera A Paulson; Yajuan J Liu; Lukáš Plank; Karen Fritchie; Carol Beadling; Tanaya L Neff; Christopher L Corless; Erin R Rudzinski; Jessica L Davis
Journal:  Mod Pathol       Date:  2021-04-13       Impact factor: 8.209

9.  Chaperones as thermodynamic sensors of drug-target interactions reveal kinase inhibitor specificities in living cells.

Authors:  Mikko Taipale; Irina Krykbaeva; Luke Whitesell; Sandro Santagata; Jianming Zhang; Qingsong Liu; Nathanael S Gray; Susan Lindquist
Journal:  Nat Biotechnol       Date:  2013-06-30       Impact factor: 54.908

Review 10.  JAK-STAT signaling in cancer: From cytokines to non-coding genome.

Authors:  Jan Pencik; Ha Thi Thanh Pham; Johannes Schmoellerl; Tahereh Javaheri; Michaela Schlederer; Zoran Culig; Olaf Merkel; Richard Moriggl; Florian Grebien; Lukas Kenner
Journal:  Cytokine       Date:  2016-06-24       Impact factor: 3.861

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.